Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutane…
Industry Peers
Medical Instruments & Supplies| Headline | Source | Time |
|---|---|---|
This week | ||
 Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns Pulse Biosciences has delivered a very strong share price run, with recent enthusiasm around its atrial fibrillation program now sitting against valuation checks that point to a stock that screens expensive rather than cheap. Over the past 3 years, Pulse Biosciences has returned about 431.5%, which puts a lot of expectation into the current price. Progress in the NANOPULSE-AF pivotal clinical study and advancing regulatory work can support hopes for future commercialisation, while any delay... | ||
 Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform Pulse Biosciences (NASDAQ:PLSE) is positioning its nanosecond pulsed field ablation technology as a potential next-generation treatment platform for atrial fibrillation and other conditions, President, CEO and Co-Chairman Paul LaViolette said during the Canaccord Genuity 46th Annual Global Growth Co | ||
Pulse Biosciences (PLSE) Prices A $75 Million Offering, Is The Stock Fully Valued? Pulse Biosciences (PLSE) is back in focus after reporting wider second quarter losses and announcing a $75 million at the market follow on equity offering, a combination that directly affects existing shareholders. See our latest analysis for Pulse Biosciences. The recent earnings release and the $75 million at the market offering have come after a strong run in Pulse Biosciences' share price, with a 30 day share price return of 55.30% and a 90 day share price return of 73.92%. Over a longer... | ||
Older | ||
 Pulse Biosciences (PLSE) Q2 2026 Earnings Call Transcript NANOPULSE-AF enrollment hit halfway point ahead of schedule with 82 patients. | ||
 Pulse Biosciences, Inc. Q2 2026 Earnings Call Summary Moby summary of Pulse Biosciences, Inc.'s Q2 2026 earnings call | ||
 Pulse Biosciences Q2 Earnings Call Highlights Pulse Biosciences (NASDAQ:PLSE) reported second-quarter revenue of $434,000 as it accelerated clinical development of its nanosecond pulsed field ablation, or nsPFA, technology, particularly for atrial fibrillation treatment. Chief Executive Officer and Co-Chairman Paul LaViolette said the company’ | ||
Pulse Biosciences Inc (PLSE) (Q2 2026) Earnings Call Highlights: Accelerated Enrollment and ... Pulse Biosciences Inc (PLSE) surpasses halfway mark in pivotal NanoPulse-AF study, reporting 100% freedom from AF at six months and raising $57.5 million to extend cash runway through key milestones. | ||
 Pulse Biosciences, Inc (PLSE) Reports Q2 Loss, Misses Revenue Estimates Pulse Biosciences (PLSE) delivered earnings and revenue surprises of -16.13% and -38.00%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 This Little-Known Biotech Stock Just Hit a New 5-Year High Pulse Biosciences (PLSE) just hit a new 5-year high and has strong technical momentum. Shares are up more than 100% over the past 52 weeks. Revenue is projected to surge 652.38% this year and 236.71% next. Analyst sentiment is mixed, with ratings from “Strong Buy” to “Strong Sell,” reflecting its... | ||